Streetbeat News

Products Services

MSTR

Economist Peter Schiff criticized Donald Trump and MicroStrategy co-founder Michael Saylor's 'never sell your Bitcoin' strategy, questioning its logic. Schiff argued that holding Bitcoin without selling it is pointless and compared it to living in poverty. He also challenged the idea that Bitcoin's value will skyrocket due to U.S. debt inflation. Trump's recent advocacy for a national cryptocurrency stockpile and Saylor's bold Bitcoin price predictions were also highlighted.

Portfolio Pulse from Aniket Verma

July 29, 2024 | 5:19 am

BCHUSD

BSVUSD

BTCUSD

Bitcoin Cash and Bitcoin SV outperformed Bitcoin in 24-hour gains, with Bitcoin Cash spiking over 7% and Bitcoin SV lifting nearly 4%. The surge in these Bitcoin spinoffs highlights growing interest among retail traders in more affordable alternatives. Bitcoin remained relatively unchanged, rising just 0.87%.

Portfolio Pulse from Aniket Verma

July 29, 2024 | 4:07 am

AMC

DIS

IMAX

The Marvel Entertainment and Walt Disney collaboration, 'Deadpool & Wolverine,' has set new box office records, grossing over $438.3 million worldwide in its opening weekend. The film's success has positively impacted the stocks of Walt Disney, AMC Entertainment Holdings, and Imax.

Portfolio Pulse from Ananya Gairola

July 29, 2024 | 3:38 am

TSLA

Tesla Inc. (NASDAQ:TSLA) aims to produce 2.77 million vehicles by 2025, a 50% increase from 2023, including new affordable models. Analyst Gary Black suggests the market underestimates Tesla's expansion into the $30,000 segment. Tesla's current capacity is 2.35 million units, with a potential maximum of 3 million. Despite recent earnings scrutiny, Tesla's resilience is noted.

Portfolio Pulse from Benzinga Neuro

July 29, 2024 | 3:36 am

ETHUSD

MATICUSD

Mark Cuban has expressed his willingness to bet on whether former President Donald Trump will exhibit a 'belly laugh' before the upcoming election on the Ethereum-based prediction market, Polymarket. This bet, while seemingly lighthearted, highlights the growing popularity of Polymarket, which operates on the Ethereum Layer-2 chain Polygon.

Portfolio Pulse from Aniket Verma

July 29, 2024 | 3:24 am

GOOG

GOOGL

Actor James Woods praised Elon Musk for his commitment to free speech, despite being blocked by Musk on X (formerly Twitter). This comes amid Alphabet Inc.'s YouTube policy changes on gun-related content, which have sparked concerns among YouTubers. The policy bans content intended to sell firearms or instruct viewers on making or installing firearm accessories.

Portfolio Pulse from Ananya Gairola

July 29, 2024 | 2:44 am

AAPL

MSFT

Leading cryptocurrencies like Bitcoin and Ethereum held their gains as Donald Trump made pro-crypto promises. Bitcoin nearly touched $69,000, and Ethereum retraced to $3,270. Futures Open Interest for both increased, signaling a potential upside breakout. Stock market futures also edged higher, with Microsoft and Apple set to report earnings. The Federal Reserve will hold an FOMC meeting this week.

Portfolio Pulse from Aniket Verma

July 29, 2024 | 2:30 am

NIO

TSLA

XPEV

The rapid increase in new energy vehicles (NEVs) in China has led to financial challenges for insurers, who are struggling to turn a profit despite higher premiums. Factors such as higher loss ratios, expensive battery repairs, and increased mileage in ride-hailing contribute to the issue. The National Financial Regulatory Administration (NFRA) is considering reforms to allow more flexible premium settings.

Portfolio Pulse from Benzinga Neuro

July 29, 2024 | 1:56 am

LGVN

Longeveron Inc. (NASDAQ:LGVN) announced positive results from its Phase 2a clinical trial of Lomecel-B for mild Alzheimer's Disease. The study met its key objectives, supporting a favorable benefit/risk profile. The results were presented at the Alzheimer’s Association International Conference (AAIC) 2024.

Portfolio Pulse from charles@benzinga.com

July 28, 2024 | 10:56 pm

AVXL

Anavex Life Sciences Corp. (NASDAQ:AVXL) announced that its drug blarcamesine significantly slowed clinical decline in early Alzheimer's disease patients in a Phase IIb/III study. The primary cognitive endpoint ADAS-Cog13 showed significant improvement, while the functional endpoint ADCS-ADL trended positive but did not reach significance. The study also showed significant results in secondary endpoints and biomarkers.

Portfolio Pulse from charles@benzinga.com

July 28, 2024 | 10:53 pm